



S/N 10/022,609

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	VANDLEN ET AL.	Examiner:	R. HAYES
Serial No.:	10/022,609	Group Art Unit:	1647
Filed:	DECEMBER 17, 2001	Docket No.:	11669.171USC5
Confirmation No.:	5365	Customer No.:	23552
Title:	STRUCTURE, PRODUCTION AND USE OF HEREGULIN 2 LIGANDS		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 408493007 US
Date of Deposit: January 19, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Mail Stop RCE, P.O. Box 1450, Alexandria, VA 22313-1450.

By:

Name: Sheryl A. Boerboom

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop RCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.



Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: January 19, 2005

Katherine M. Kowalchyk
Katherine M. Kowalchyk
Reg. No. 36,848



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.171USC5	Application Number: 10/022,609
	Applicant: VANDLEN ET AL.	
	Filing Date: DECEMBER 17, 2001	Group Art Unit: 1647

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,816,567	03/28/1989	CABILLY ET AL.			
	5,578,482	11/26/1996	LIPPMAN ET AL.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	9107566.3	04/10/1991	GB				
	WO 92/20798	11/26/1992	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Paper No. 7 dated March 20, 1995 from the history of Serial No. 08/096,277, now U.S. Patent No. 5,578,482, authored by Lawrence H. Posorske, publicly available as of the issue date of the patent of November 26, 1996
		Paper No. 8 dated June 29, 1995 from file history of Serial No. 08/096,277, now U.S. Patent No. 5,578,482, authored by U.S. PTO Examiner, publicly available as of issue date of the patent of November 26, 1996
		Lupu, R. et al., "The role of erbB2 signal transduction pathways in human breast cancer", <i>Breast Cancer Research and Treatment</i> , 27:83-93 (1993)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	